Your fact-checks will appear here
Preclinical studies demonstrating ivermectin's anticancer effects, including cytotoxicity, anti-proliferative, and anti-angiogenic effects in various cancer models.
Standard single-dose antiparasitic regimens of oral ivermectin produce plasma levels in the low nanomolar range, whereas multi‑day oncology schedules being tested raise both total exposure and peak le...
Preclinical work identifies strongest anticancer signals for ivermectin in breast cancer, hematologic malignancies (notably leukemia), hepatocellular carcinoma, and several drug-resistant solid tumor ...
Preclinical literature shows repeated, drug‑level interactions between ivermectin and multiple chemotherapy or targeted agents—mostly beneficial pharmacodynamic synergies (enhanced tumor cell kill, re...